<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33567654</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
              <Day>08</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pathological Circulating Factors in Moyamoya Disease.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">1696</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22041696</ELocationID>
        <Abstract>
          <AbstractText>Moyamoya disease (MMD) is a cerebrovascular disease that presents with vascular stenosis and a hazy network of collateral formations in angiography. However, the detailed pathogenic pathway remains unknown. Studies have indicated that in addition to variations in the of genetic factor <i>RNF213</i>, unusual circulating angiogenetic factors observed in patients with MMD may play a critical role in producing "Moyamoya vessels". Circulating angiogenetic factors, such as growth factors, vascular progenitor cells, cytokines, inflammatory factors, and other circulating proteins, could promote intimal hyperplasia in vessels and excessive collateral formation with defect structures through endothelial hyperplasia, smooth muscle migration, and atypical neovascularization. This study summarizes the hypothesized pathophysiology of how these circulating factors affect MMD and the interactive modulation between them.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Yao-Ching</ForeName>
            <Initials>YC</Initials>
            <AffiliationInfo>
              <Affiliation>Taipei Neuroscience Institute, Taipei Medical University, Taipei 11031, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Ling-Fei</ForeName>
            <Initials>LF</Initials>
            <AffiliationInfo>
              <Affiliation>Taipei Neuroscience Institute, Taipei Medical University, Taipei 11031, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Chaur-Jong</ForeName>
            <Initials>CJ</Initials>
            <Identifier Source="ORCID">0000-0002-4900-5967</Identifier>
            <AffiliationInfo>
              <Affiliation>Taipei Neuroscience Institute, Taipei Medical University, Taipei 11031, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tu</LastName>
            <ForeName>Yong-Kwang</ForeName>
            <Initials>YK</Initials>
            <AffiliationInfo>
              <Affiliation>Taipei Neuroscience Institute, Taipei Medical University, Taipei 11031, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009072" MajorTopicYN="N">Moyamoya Disease</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Moyamoya disease</Keyword>
        <Keyword MajorTopicYN="N">RNF213</Keyword>
        <Keyword MajorTopicYN="N">cerebrovascular disease</Keyword>
        <Keyword MajorTopicYN="N">circulating factor</Keyword>
        <Keyword MajorTopicYN="N">collateral formations</Keyword>
        <Keyword MajorTopicYN="N">growth factors</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>1</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33567654</ArticleId>
        <ArticleId IdType="pmc">PMC7915927</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms22041696</ArticleId>
        <ArticleId IdType="pii">ijms22041696</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Suzuki J., Takaku A. Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch. Neurol. 1969;20:288–299. doi: 10.1001/archneur.1969.00480090076012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1969.00480090076012</ArticleId>
            <ArticleId IdType="pubmed">5775283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott R.M., Smith E.R. Moyamoya disease and moyamoya syndrome. N. Engl. J. Med. 2009;360:1226–1237. doi: 10.1056/NEJMra0804622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra0804622</ArticleId>
            <ArticleId IdType="pubmed">19297575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shang S., Zhou D., Ya J., Li S., Yang Q., Ding Y., Ji X., Meng R. Progress in moyamoya disease. Neurosurg. Rev. 2020;43:371–382. doi: 10.1007/s10143-018-0994-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10143-018-0994-5</ArticleId>
            <ArticleId IdType="pubmed">29911252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goto Y., Yonekawa Y. Worldwide distribution of moyamoya disease. Neurol. Med. Chir. 1992;32:883–886. doi: 10.2176/nmc.32.883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2176/nmc.32.883</ArticleId>
            <ArticleId IdType="pubmed">1282678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuroda S., Houkin K. Moyamoya disease: Current concepts and future perspectives. Lancet Neurol. 2008;7:1056–1066. doi: 10.1016/S1474-4422(08)70240-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(08)70240-0</ArticleId>
            <ArticleId IdType="pubmed">18940695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamada F., Aoki Y., Narisawa A., Abe Y., Komatsuzaki S., Kikuchi A., Kanno J., Niihori T., Ono M., Ishii N., et al.  A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J. Hum. Genet. 2011;56:34–40. doi: 10.1038/jhg.2010.132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jhg.2010.132</ArticleId>
            <ArticleId IdType="pubmed">21048783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freemont P.S. The RING finger. A novel protein sequence motif related to the zinc finger. Ann. N. Y. Acad. Sci. 1993;684:174–192. doi: 10.1111/j.1749-6632.1993.tb32280.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.1993.tb32280.x</ArticleId>
            <ArticleId IdType="pubmed">8317827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elangovan M., Choi E.S., Jang B.G., Kim M.S., Yoo Y.J. The ubiquitin-interacting motif of 26S proteasome subunit S5a induces A549 lung cancer cell death. Biochem. Biophys Res. Commun. 2007;364:226–230. doi: 10.1016/j.bbrc.2007.09.127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2007.09.127</ArticleId>
            <ArticleId IdType="pubmed">17949686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W., Morito D., Takashima S., Mineharu Y., Kobayashi H., Hitomi T., Hashikata H., Matsuura N., Yamazaki S., Toyoda A., et al.  Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS ONE. 2011;6:e22542.  doi: 10.1371/journal.pone.0022542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0022542</ArticleId>
            <ArticleId IdType="pmc">PMC3140517</ArticleId>
            <ArticleId IdType="pubmed">21799892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bang O.Y., Chung J.W., Kim S.J., Oh M.J., Kim S.Y., Cho Y.H., Cha J., Yeon J.Y., Kim K.H., Kim G.M., et al.  Caveolin-1, Ring finger protein 213, and endothelial function in Moyamoya disease. Int. J. Stroke. 2016;11:999–1008. doi: 10.1177/1747493016662039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1747493016662039</ArticleId>
            <ArticleId IdType="pubmed">27462098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujimura M., Sonobe S., Nishijima Y., Niizuma K., Sakata H., Kure S., Tominaga T. Genetics and biomarkers of Moyamoya disease: Significance of RNF213 as a susceptibility gene. J. Stroke. 2014;16:65–72. doi: 10.5853/jos.2014.16.2.65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5853/jos.2014.16.2.65</ArticleId>
            <ArticleId IdType="pmc">PMC4060268</ArticleId>
            <ArticleId IdType="pubmed">24949311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang H.S., Kim J.H., Phi J.H., Kim Y.Y., Kim J.E., Wang K.C., Cho B.K., Kim S.K. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J. Neurol. Neurosurg. Psychiatry. 2010;81:673–678. doi: 10.1136/jnnp.2009.191817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2009.191817</ArticleId>
            <ArticleId IdType="pubmed">19965844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakamoto S., Kiura Y., Yamasaki F., Shibukawa M., Ohba S., Shrestha P., Sugiyama K., Kurisu K. Expression of vascular endothelial growth factor in dura mater of patients with moyamoya disease. Neurosurg. Rev. 2008;31:77–81. doi: 10.1007/s10143-007-0102-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10143-007-0102-8</ArticleId>
            <ArticleId IdType="pubmed">17912564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park Y.S., Jeon Y.J., Kim H.S., Chae K.Y., Oh S.H., Han I.B., Kim H.S., Kim W.C., Kim O.J., Kim T.G., et al.  The role of VEGF and KDR polymorphisms in moyamoya disease and collateral revascularization. PLoS ONE. 2012;7:e47158.  doi: 10.1371/journal.pone.0047158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0047158</ArticleId>
            <ArticleId IdType="pmc">PMC3470587</ArticleId>
            <ArticleId IdType="pubmed">23077562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He J., Wang R., Zhang D., Zhang Y., Zhang Q., Zhao J. Expression of circulating vascular endothelial growth factor-antagonizing cytokines and vascular stabilizing factors prior to and following bypass surgery in patients with moyamoya disease. Exp. Ther. Med. 2014;8:302–308. doi: 10.3892/etm.2014.1713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/etm.2014.1713</ArticleId>
            <ArticleId IdType="pmc">PMC4061224</ArticleId>
            <ArticleId IdType="pubmed">24944638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi A., Sawamura Y., Houkin K., Kamiyama H., Abe H. The cerebrospinal fluid in patients with moyamoya disease (spontaneous occlusion of the circle of Willis) contains high level of basic fibroblast growth factor. Neurosci. Lett. 1993;160:214–216. doi: 10.1016/0304-3940(93)90416-I.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0304-3940(93)90416-I</ArticleId>
            <ArticleId IdType="pubmed">8247356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshimoto T., Houkin K., Takahashi A., Abe H. Angiogenic factors in moyamoya disease. Stroke. 1996;27:2160–2165. doi: 10.1161/01.STR.27.12.2160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.STR.27.12.2160</ArticleId>
            <ArticleId IdType="pubmed">8969773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nanba R., Kuroda S., Ishikawa T., Houkin K., Iwasaki Y. Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease. Stroke. 2004;35:2837–2842. doi: 10.1161/01.STR.0000148237.13659.e6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.STR.0000148237.13659.e6</ArticleId>
            <ArticleId IdType="pubmed">15528455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto M., Aoyagi M., Tajima S., Wachi H., Fukai N., Matsushima Y., Yamamoto K. Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with Moyamoya disease. Stroke. 1997;28:1733–1738. doi: 10.1161/01.STR.28.9.1733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.STR.28.9.1733</ArticleId>
            <ArticleId IdType="pubmed">9303017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J.H., Jung J.H., Phi J.H., Kang H.S., Kim J.E., Chae J.H., Kim S.J., Kim Y.H., Kim Y.Y., Cho B.K., et al.  Decreased level and defective function of circulating endothelial progenitor cells in children with moyamoya disease. J. Neurosci. Res. 2010;88:510–518. doi: 10.1002/jnr.22228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jnr.22228</ArticleId>
            <ArticleId IdType="pubmed">19774676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rafat N., Beck G., Pena-Tapia P.G., Schmiedek P., Vajkoczy P. Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease. Stroke. 2009;40:432–438. doi: 10.1161/STROKEAHA.108.529420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/STROKEAHA.108.529420</ArticleId>
            <ArticleId IdType="pubmed">19095988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshihara T., Taguchi A., Matsuyama T., Shimizu Y., Kikuchi-Taura A., Soma T., Stern D.M., Yoshikawa H., Kasahara Y., Moriwaki H., et al.  Increase in circulating CD34-positive cells in patients with angiographic evidence of moyamoya-like vessels. J. Cereb. Blood Flow Metab. 2008;28:1086–1089. doi: 10.1038/jcbfm.2008.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jcbfm.2008.1</ArticleId>
            <ArticleId IdType="pubmed">18231114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi J.W., Son S.M., Mook-Jung I., Moon Y.J., Lee J.Y., Wang K.C., Kang H.S., Phi J.H., Choi S.A., Chong S., et al.  Mitochondrial abnormalities related to the dysfunction of circulating endothelial colony-forming cells in moyamoya disease. J. Neurosurg. 2018;129:1151–1159. doi: 10.3171/2017.5.JNS17147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2017.5.JNS17147</ArticleId>
            <ArticleId IdType="pubmed">29219755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung K.H., Chu K., Lee S.T., Park H.K., Kim D.H., Kim J.H., Bahn J.J., Song E.C., Kim M., Lee S.K., et al.  Circulating endothelial progenitor cells as a pathogenetic marker of moyamoya disease. J. Cereb. Blood Flow Metab. 2008;28:1795–1803. doi: 10.1038/jcbfm.2008.67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jcbfm.2008.67</ArticleId>
            <ArticleId IdType="pubmed">18612318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J.Y., Moon Y.J., Lee H.O., Park A.K., Choi S.A., Wang K.C., Han J.W., Joung J.G., Kang H.S., Kim J.E., et al.  Deregulation of retinaldehyde dehydrogenase 2 leads to defective angiogenic function of endothelial colony-forming cells in pediatric Moyamoya disease. Arterioscler. Thromb. Vasc. Biol. 2015;35:1670–1677. doi: 10.1161/ATVBAHA.115.305363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/ATVBAHA.115.305363</ArticleId>
            <ArticleId IdType="pubmed">26023078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo D.C., Papke C.L., Tran-Fadulu V., Regalado E.S., Avidan N., Johnson R.J., Kim D.H., Pannu H., Willing M.C., Sparks E., et al.  Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am. J. Hum. Genet. 2009;84:617–627. doi: 10.1016/j.ajhg.2009.04.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajhg.2009.04.007</ArticleId>
            <ArticleId IdType="pmc">PMC2680995</ArticleId>
            <ArticleId IdType="pubmed">19409525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang H.S., Moon Y.J., Kim Y.Y., Park W.Y., Park A.K., Wang K.C., Kim J.E., Phi J.H., Lee J.Y., Kim S.K. Smooth-muscle progenitor cells isolated from patients with moyamoya disease: Novel experimental cell model. J. Neurosurg. 2014;120:415–425. doi: 10.3171/2013.9.JNS131000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2013.9.JNS131000</ArticleId>
            <ArticleId IdType="pubmed">24160477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hojo M., Hoshimaru M., Miyamoto S., Taki W., Nagata I., Asahi M., Matsuura N., Ishizaki R., Kikuchi H., Hashimoto N. Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. J. Neurosurg. 1998;89:623–629. doi: 10.3171/jns.1998.89.4.0623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/jns.1998.89.4.0623</ArticleId>
            <ArticleId IdType="pubmed">9761057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weng L., Cao X., Han L., Zhao H., Qiu S., Yan Y., Wang X., Chen X., Zheng W., Xu X., et al.  Association of increased Treg and Th17 with pathogenesis of moyamoya disease. Sci. Rep. 2017;7:3071. doi: 10.1038/s41598-017-03278-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-03278-8</ArticleId>
            <ArticleId IdType="pmc">PMC5465197</ArticleId>
            <ArticleId IdType="pubmed">28596558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S.K., Yoo J.I., Cho B.K., Hong S.J., Kim Y.K., Moon J.A., Kim J.H., Chung Y.N., Wang K.C. Elevation of CRABP-I in the cerebrospinal fluid of patients with Moyamoya disease. Stroke. 2003;34:2835–2841. doi: 10.1161/01.STR.0000100159.43123.D7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.STR.0000100159.43123.D7</ArticleId>
            <ArticleId IdType="pubmed">14605320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blecharz-Lang K.G., Prinz V., Burek M., Frey D., Schenkel T., Krug S.M., Fromm M., Vajkoczy P. Gelatinolytic activity of autocrine matrix metalloproteinase-9 leads to endothelial de-arrangement in Moyamoya disease. J. Cereb. Blood Flow Metab. 2018;38:1940–1953. doi: 10.1177/0271678X18768443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0271678X18768443</ArticleId>
            <ArticleId IdType="pmc">PMC6259317</ArticleId>
            <ArticleId IdType="pubmed">29633884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujimura M., Watanabe M., Narisawa A., Shimizu H., Tominaga T. Increased expression of serum Matrix Metalloproteinase-9 in patients with Moyamoya disease. Surg. Neurol. 2009;72:476–480. doi: 10.1016/j.surneu.2008.10.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.surneu.2008.10.009</ArticleId>
            <ArticleId IdType="pubmed">19147196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takagi Y., Kikuta K., Nozaki K., Fujimoto M., Hayashi J., Imamura H., Hashimoto N. Expression of hypoxia-inducing factor-1 alpha and endoglin in intimal hyperplasia of the middle cerebral artery of patients with Moyamoya disease. Neurosurgery. 2007;60:338–345. doi: 10.1227/01.NEU.0000249275.87310.FF.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1227/01.NEU.0000249275.87310.FF</ArticleId>
            <ArticleId IdType="pubmed">17290185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin R., Xie Z., Zhang J., Xu H., Su H., Tan X., Tian D., Su M. Clinical and immunopathological features of Moyamoya disease. PLoS ONE. 2012;7:e36386.  doi: 10.1371/journal.pone.0036386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0036386</ArticleId>
            <ArticleId IdType="pmc">PMC3338675</ArticleId>
            <ArticleId IdType="pubmed">22558457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujimura M., Fujimura T., Kakizaki A., Sato-Maeda M., Niizuma K., Tomata Y., Aiba S., Tominaga T. Increased serum production of soluble CD163 and CXCL5 in patients with moyamoya disease: Involvement of intrinsic immune reaction in its pathogenesis. Brain Res. 2018;1679:39–44. doi: 10.1016/j.brainres.2017.11.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2017.11.013</ArticleId>
            <ArticleId IdType="pubmed">29174692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung J.W., Kim D.H., Oh M.J., Cho Y.H., Kim E.H., Moon G.J., Ki C.S., Cha J., Kim K.H., Jeon P., et al.  Cav-1 (Caveolin-1) and arterial remodeling in adult Moyamoya disease. Stroke. 2018;49:2597–2604. doi: 10.1161/STROKEAHA.118.021888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/STROKEAHA.118.021888</ArticleId>
            <ArticleId IdType="pubmed">30355208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noda A., Suzuki Y., Takayasu M., Watanabe K., Takagi T., Hara M., Yoshida J. Elevation of nitric oxide metabolites in the cerebrospinal fluid of patients with moyamoya disease. Acta Neurochir. 2000;142:1275–1279. doi: 10.1007/s007010070025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s007010070025</ArticleId>
            <ArticleId IdType="pubmed">11201643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling—In control of vascular function. Nat. Rev. Mol. Cell Biol. 2006;7:359–371. doi: 10.1038/nrm1911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm1911</ArticleId>
            <ArticleId IdType="pubmed">16633338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaipersad A.S., Lip G.Y., Silverman S., Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J. Am. Coll. Cardiol. 2014;63:1–11. doi: 10.1016/j.jacc.2013.09.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2013.09.019</ArticleId>
            <ArticleId IdType="pubmed">24140662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto M., Aoyagi M., Fukai N., Matsushima Y., Yamamoto K. Differences in cellular responses to mitogens in arterial smooth muscle cells derived from patients with moyamoya disease. Stroke. 1998;29:1188–1193. doi: 10.1161/01.STR.29.6.1188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.STR.29.6.1188</ArticleId>
            <ArticleId IdType="pubmed">9626293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morishita R., Sakaki M., Yamamoto K., Iguchi S., Aoki M., Yamasaki K., Matsumoto K., Nakamura T., Lawn R., Ogihara T., et al.  Impairment of collateral formation in lipoprotein(a) transgenic mice: Therapeutic angiogenesis induced by human hepatocyte growth factor gene. Circulation. 2002;105:1491–1496. doi: 10.1161/01.CIR.0000012146.07240.FD.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.CIR.0000012146.07240.FD</ArticleId>
            <ArticleId IdType="pubmed">11914260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houkin K., Ito M., Sugiyama T., Shichinohe H., Nakayama N., Kazumata K., Kuroda S. Review of past research and current concepts on the etiology of moyamoya disease. Neurol. Med. Chir. 2012;52:267–277. doi: 10.2176/nmc.52.267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2176/nmc.52.267</ArticleId>
            <ArticleId IdType="pubmed">22688062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paschalaki K.E., Randi A.M. Recent advances in endothelial colony forming cells toward their use in clinical translation. Front. Med. 2018;5:295. doi: 10.3389/fmed.2018.00295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmed.2018.00295</ArticleId>
            <ArticleId IdType="pmc">PMC6205967</ArticleId>
            <ArticleId IdType="pubmed">30406106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tokunaga K., Date I. Moyamoya disease. Brain Nerve. 2008;60:37–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18232331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boylan J.F., Gudas L.J. The level of CRABP-I expression influences the amounts and types of all-trans-retinoic acid metabolites in F9 teratocarcinoma stem cells. J. Biol. Chem. 1992;267:21486–21491. doi: 10.1016/S0021-9258(19)36635-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0021-9258(19)36635-9</ArticleId>
            <ArticleId IdType="pubmed">1328234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mikami T., Suzuki H., Komatsu K., Mikuni N. Influence of Inflammatory disease on the pathophysiology of Moyamoya disease and quasi-Moyamoya disease. Neurol. Med. Chir. 2019;59:361–370. doi: 10.2176/nmc.ra.2019-0059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2176/nmc.ra.2019-0059</ArticleId>
            <ArticleId IdType="pmc">PMC6796064</ArticleId>
            <ArticleId IdType="pubmed">31281171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonveaux P., Martinive P., DeWever J., Batova Z., Daneau G., Pelat M., Ghisdal P., Gregoire V., Dessy C., Balligand J.L., et al.  Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ. Res. 2004;95:154–161. doi: 10.1161/01.RES.0000136344.27825.72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.RES.0000136344.27825.72</ArticleId>
            <ArticleId IdType="pubmed">15205364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park Y.S., Min K.T., Kim T.G., Lee Y.H., Cheong H.J., Yeom I.S., Choi J.U., Kim D.S., Kim N.K. Age-specific eNOS polymorphisms in moyamoya disease. Childs Nerv. Syst. 2011;27:1919–1926. doi: 10.1007/s00381-011-1504-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00381-011-1504-z</ArticleId>
            <ArticleId IdType="pubmed">21691823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai D., Lu Q., Huang Q., Yang P., Hong B., Xu Y., Zhao W., Liu J., Li Q. Serum miRNA signature in Moyamoya disease. PLoS ONE. 2014;9:e102382.  doi: 10.1371/journal.pone.0102382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0102382</ArticleId>
            <ArticleId IdType="pmc">PMC4122349</ArticleId>
            <ArticleId IdType="pubmed">25093848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uchino H., Ito M., Kazumata K., Hama Y., Hamauchi S., Terasaka S., Sasaki H., Houkin K. Circulating miRNome profiling in Moyamoya disease-discordant monozygotic twins and endothelial microRNA expression analysis using iPS cell line. BMC Med. Genom. 2018;11:72.  doi: 10.1186/s12920-018-0385-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12920-018-0385-3</ArticleId>
            <ArticleId IdType="pmc">PMC6114494</ArticleId>
            <ArticleId IdType="pubmed">30157848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee M.J., Fallen S., Zhou Y., Baxter D., Scherler K., Kuo M.F., Wang K. The impact of Moyamoya disease and RNF213 mutations on the spectrum of plasma protein and MicroRNA. J. Clin. Med. 2019;8:1648.  doi: 10.3390/jcm8101648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm8101648</ArticleId>
            <ArticleId IdType="pmc">PMC6832561</ArticleId>
            <ArticleId IdType="pubmed">31658621</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33567654</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
              <Day>08</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pathological Circulating Factors in Moyamoya Disease.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">1696</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22041696</ELocationID>
        <Abstract>
          <AbstractText>Moyamoya disease (MMD) is a cerebrovascular disease that presents with vascular stenosis and a hazy network of collateral formations in angiography. However, the detailed pathogenic pathway remains unknown. Studies have indicated that in addition to variations in the of genetic factor <i>RNF213</i>, unusual circulating angiogenetic factors observed in patients with MMD may play a critical role in producing "Moyamoya vessels". Circulating angiogenetic factors, such as growth factors, vascular progenitor cells, cytokines, inflammatory factors, and other circulating proteins, could promote intimal hyperplasia in vessels and excessive collateral formation with defect structures through endothelial hyperplasia, smooth muscle migration, and atypical neovascularization. This study summarizes the hypothesized pathophysiology of how these circulating factors affect MMD and the interactive modulation between them.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Yao-Ching</ForeName>
            <Initials>YC</Initials>
            <AffiliationInfo>
              <Affiliation>Taipei Neuroscience Institute, Taipei Medical University, Taipei 11031, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Ling-Fei</ForeName>
            <Initials>LF</Initials>
            <AffiliationInfo>
              <Affiliation>Taipei Neuroscience Institute, Taipei Medical University, Taipei 11031, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Chaur-Jong</ForeName>
            <Initials>CJ</Initials>
            <Identifier Source="ORCID">0000-0002-4900-5967</Identifier>
            <AffiliationInfo>
              <Affiliation>Taipei Neuroscience Institute, Taipei Medical University, Taipei 11031, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tu</LastName>
            <ForeName>Yong-Kwang</ForeName>
            <Initials>YK</Initials>
            <AffiliationInfo>
              <Affiliation>Taipei Neuroscience Institute, Taipei Medical University, Taipei 11031, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009072" MajorTopicYN="N">Moyamoya Disease</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Moyamoya disease</Keyword>
        <Keyword MajorTopicYN="N">RNF213</Keyword>
        <Keyword MajorTopicYN="N">cerebrovascular disease</Keyword>
        <Keyword MajorTopicYN="N">circulating factor</Keyword>
        <Keyword MajorTopicYN="N">collateral formations</Keyword>
        <Keyword MajorTopicYN="N">growth factors</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>1</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33567654</ArticleId>
        <ArticleId IdType="pmc">PMC7915927</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms22041696</ArticleId>
        <ArticleId IdType="pii">ijms22041696</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Suzuki J., Takaku A. Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch. Neurol. 1969;20:288–299. doi: 10.1001/archneur.1969.00480090076012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1969.00480090076012</ArticleId>
            <ArticleId IdType="pubmed">5775283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott R.M., Smith E.R. Moyamoya disease and moyamoya syndrome. N. Engl. J. Med. 2009;360:1226–1237. doi: 10.1056/NEJMra0804622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra0804622</ArticleId>
            <ArticleId IdType="pubmed">19297575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shang S., Zhou D., Ya J., Li S., Yang Q., Ding Y., Ji X., Meng R. Progress in moyamoya disease. Neurosurg. Rev. 2020;43:371–382. doi: 10.1007/s10143-018-0994-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10143-018-0994-5</ArticleId>
            <ArticleId IdType="pubmed">29911252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goto Y., Yonekawa Y. Worldwide distribution of moyamoya disease. Neurol. Med. Chir. 1992;32:883–886. doi: 10.2176/nmc.32.883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2176/nmc.32.883</ArticleId>
            <ArticleId IdType="pubmed">1282678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuroda S., Houkin K. Moyamoya disease: Current concepts and future perspectives. Lancet Neurol. 2008;7:1056–1066. doi: 10.1016/S1474-4422(08)70240-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(08)70240-0</ArticleId>
            <ArticleId IdType="pubmed">18940695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamada F., Aoki Y., Narisawa A., Abe Y., Komatsuzaki S., Kikuchi A., Kanno J., Niihori T., Ono M., Ishii N., et al.  A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J. Hum. Genet. 2011;56:34–40. doi: 10.1038/jhg.2010.132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jhg.2010.132</ArticleId>
            <ArticleId IdType="pubmed">21048783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freemont P.S. The RING finger. A novel protein sequence motif related to the zinc finger. Ann. N. Y. Acad. Sci. 1993;684:174–192. doi: 10.1111/j.1749-6632.1993.tb32280.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.1993.tb32280.x</ArticleId>
            <ArticleId IdType="pubmed">8317827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elangovan M., Choi E.S., Jang B.G., Kim M.S., Yoo Y.J. The ubiquitin-interacting motif of 26S proteasome subunit S5a induces A549 lung cancer cell death. Biochem. Biophys Res. Commun. 2007;364:226–230. doi: 10.1016/j.bbrc.2007.09.127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2007.09.127</ArticleId>
            <ArticleId IdType="pubmed">17949686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W., Morito D., Takashima S., Mineharu Y., Kobayashi H., Hitomi T., Hashikata H., Matsuura N., Yamazaki S., Toyoda A., et al.  Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS ONE. 2011;6:e22542.  doi: 10.1371/journal.pone.0022542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0022542</ArticleId>
            <ArticleId IdType="pmc">PMC3140517</ArticleId>
            <ArticleId IdType="pubmed">21799892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bang O.Y., Chung J.W., Kim S.J., Oh M.J., Kim S.Y., Cho Y.H., Cha J., Yeon J.Y., Kim K.H., Kim G.M., et al.  Caveolin-1, Ring finger protein 213, and endothelial function in Moyamoya disease. Int. J. Stroke. 2016;11:999–1008. doi: 10.1177/1747493016662039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1747493016662039</ArticleId>
            <ArticleId IdType="pubmed">27462098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujimura M., Sonobe S., Nishijima Y., Niizuma K., Sakata H., Kure S., Tominaga T. Genetics and biomarkers of Moyamoya disease: Significance of RNF213 as a susceptibility gene. J. Stroke. 2014;16:65–72. doi: 10.5853/jos.2014.16.2.65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5853/jos.2014.16.2.65</ArticleId>
            <ArticleId IdType="pmc">PMC4060268</ArticleId>
            <ArticleId IdType="pubmed">24949311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang H.S., Kim J.H., Phi J.H., Kim Y.Y., Kim J.E., Wang K.C., Cho B.K., Kim S.K. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J. Neurol. Neurosurg. Psychiatry. 2010;81:673–678. doi: 10.1136/jnnp.2009.191817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2009.191817</ArticleId>
            <ArticleId IdType="pubmed">19965844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakamoto S., Kiura Y., Yamasaki F., Shibukawa M., Ohba S., Shrestha P., Sugiyama K., Kurisu K. Expression of vascular endothelial growth factor in dura mater of patients with moyamoya disease. Neurosurg. Rev. 2008;31:77–81. doi: 10.1007/s10143-007-0102-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10143-007-0102-8</ArticleId>
            <ArticleId IdType="pubmed">17912564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park Y.S., Jeon Y.J., Kim H.S., Chae K.Y., Oh S.H., Han I.B., Kim H.S., Kim W.C., Kim O.J., Kim T.G., et al.  The role of VEGF and KDR polymorphisms in moyamoya disease and collateral revascularization. PLoS ONE. 2012;7:e47158.  doi: 10.1371/journal.pone.0047158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0047158</ArticleId>
            <ArticleId IdType="pmc">PMC3470587</ArticleId>
            <ArticleId IdType="pubmed">23077562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He J., Wang R., Zhang D., Zhang Y., Zhang Q., Zhao J. Expression of circulating vascular endothelial growth factor-antagonizing cytokines and vascular stabilizing factors prior to and following bypass surgery in patients with moyamoya disease. Exp. Ther. Med. 2014;8:302–308. doi: 10.3892/etm.2014.1713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/etm.2014.1713</ArticleId>
            <ArticleId IdType="pmc">PMC4061224</ArticleId>
            <ArticleId IdType="pubmed">24944638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi A., Sawamura Y., Houkin K., Kamiyama H., Abe H. The cerebrospinal fluid in patients with moyamoya disease (spontaneous occlusion of the circle of Willis) contains high level of basic fibroblast growth factor. Neurosci. Lett. 1993;160:214–216. doi: 10.1016/0304-3940(93)90416-I.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0304-3940(93)90416-I</ArticleId>
            <ArticleId IdType="pubmed">8247356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshimoto T., Houkin K., Takahashi A., Abe H. Angiogenic factors in moyamoya disease. Stroke. 1996;27:2160–2165. doi: 10.1161/01.STR.27.12.2160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.STR.27.12.2160</ArticleId>
            <ArticleId IdType="pubmed">8969773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nanba R., Kuroda S., Ishikawa T., Houkin K., Iwasaki Y. Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease. Stroke. 2004;35:2837–2842. doi: 10.1161/01.STR.0000148237.13659.e6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.STR.0000148237.13659.e6</ArticleId>
            <ArticleId IdType="pubmed">15528455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto M., Aoyagi M., Tajima S., Wachi H., Fukai N., Matsushima Y., Yamamoto K. Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with Moyamoya disease. Stroke. 1997;28:1733–1738. doi: 10.1161/01.STR.28.9.1733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.STR.28.9.1733</ArticleId>
            <ArticleId IdType="pubmed">9303017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J.H., Jung J.H., Phi J.H., Kang H.S., Kim J.E., Chae J.H., Kim S.J., Kim Y.H., Kim Y.Y., Cho B.K., et al.  Decreased level and defective function of circulating endothelial progenitor cells in children with moyamoya disease. J. Neurosci. Res. 2010;88:510–518. doi: 10.1002/jnr.22228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jnr.22228</ArticleId>
            <ArticleId IdType="pubmed">19774676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rafat N., Beck G., Pena-Tapia P.G., Schmiedek P., Vajkoczy P. Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease. Stroke. 2009;40:432–438. doi: 10.1161/STROKEAHA.108.529420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/STROKEAHA.108.529420</ArticleId>
            <ArticleId IdType="pubmed">19095988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshihara T., Taguchi A., Matsuyama T., Shimizu Y., Kikuchi-Taura A., Soma T., Stern D.M., Yoshikawa H., Kasahara Y., Moriwaki H., et al.  Increase in circulating CD34-positive cells in patients with angiographic evidence of moyamoya-like vessels. J. Cereb. Blood Flow Metab. 2008;28:1086–1089. doi: 10.1038/jcbfm.2008.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jcbfm.2008.1</ArticleId>
            <ArticleId IdType="pubmed">18231114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi J.W., Son S.M., Mook-Jung I., Moon Y.J., Lee J.Y., Wang K.C., Kang H.S., Phi J.H., Choi S.A., Chong S., et al.  Mitochondrial abnormalities related to the dysfunction of circulating endothelial colony-forming cells in moyamoya disease. J. Neurosurg. 2018;129:1151–1159. doi: 10.3171/2017.5.JNS17147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2017.5.JNS17147</ArticleId>
            <ArticleId IdType="pubmed">29219755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung K.H., Chu K., Lee S.T., Park H.K., Kim D.H., Kim J.H., Bahn J.J., Song E.C., Kim M., Lee S.K., et al.  Circulating endothelial progenitor cells as a pathogenetic marker of moyamoya disease. J. Cereb. Blood Flow Metab. 2008;28:1795–1803. doi: 10.1038/jcbfm.2008.67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jcbfm.2008.67</ArticleId>
            <ArticleId IdType="pubmed">18612318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J.Y., Moon Y.J., Lee H.O., Park A.K., Choi S.A., Wang K.C., Han J.W., Joung J.G., Kang H.S., Kim J.E., et al.  Deregulation of retinaldehyde dehydrogenase 2 leads to defective angiogenic function of endothelial colony-forming cells in pediatric Moyamoya disease. Arterioscler. Thromb. Vasc. Biol. 2015;35:1670–1677. doi: 10.1161/ATVBAHA.115.305363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/ATVBAHA.115.305363</ArticleId>
            <ArticleId IdType="pubmed">26023078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo D.C., Papke C.L., Tran-Fadulu V., Regalado E.S., Avidan N., Johnson R.J., Kim D.H., Pannu H., Willing M.C., Sparks E., et al.  Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am. J. Hum. Genet. 2009;84:617–627. doi: 10.1016/j.ajhg.2009.04.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajhg.2009.04.007</ArticleId>
            <ArticleId IdType="pmc">PMC2680995</ArticleId>
            <ArticleId IdType="pubmed">19409525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang H.S., Moon Y.J., Kim Y.Y., Park W.Y., Park A.K., Wang K.C., Kim J.E., Phi J.H., Lee J.Y., Kim S.K. Smooth-muscle progenitor cells isolated from patients with moyamoya disease: Novel experimental cell model. J. Neurosurg. 2014;120:415–425. doi: 10.3171/2013.9.JNS131000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2013.9.JNS131000</ArticleId>
            <ArticleId IdType="pubmed">24160477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hojo M., Hoshimaru M., Miyamoto S., Taki W., Nagata I., Asahi M., Matsuura N., Ishizaki R., Kikuchi H., Hashimoto N. Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. J. Neurosurg. 1998;89:623–629. doi: 10.3171/jns.1998.89.4.0623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/jns.1998.89.4.0623</ArticleId>
            <ArticleId IdType="pubmed">9761057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weng L., Cao X., Han L., Zhao H., Qiu S., Yan Y., Wang X., Chen X., Zheng W., Xu X., et al.  Association of increased Treg and Th17 with pathogenesis of moyamoya disease. Sci. Rep. 2017;7:3071. doi: 10.1038/s41598-017-03278-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-03278-8</ArticleId>
            <ArticleId IdType="pmc">PMC5465197</ArticleId>
            <ArticleId IdType="pubmed">28596558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S.K., Yoo J.I., Cho B.K., Hong S.J., Kim Y.K., Moon J.A., Kim J.H., Chung Y.N., Wang K.C. Elevation of CRABP-I in the cerebrospinal fluid of patients with Moyamoya disease. Stroke. 2003;34:2835–2841. doi: 10.1161/01.STR.0000100159.43123.D7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.STR.0000100159.43123.D7</ArticleId>
            <ArticleId IdType="pubmed">14605320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blecharz-Lang K.G., Prinz V., Burek M., Frey D., Schenkel T., Krug S.M., Fromm M., Vajkoczy P. Gelatinolytic activity of autocrine matrix metalloproteinase-9 leads to endothelial de-arrangement in Moyamoya disease. J. Cereb. Blood Flow Metab. 2018;38:1940–1953. doi: 10.1177/0271678X18768443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0271678X18768443</ArticleId>
            <ArticleId IdType="pmc">PMC6259317</ArticleId>
            <ArticleId IdType="pubmed">29633884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujimura M., Watanabe M., Narisawa A., Shimizu H., Tominaga T. Increased expression of serum Matrix Metalloproteinase-9 in patients with Moyamoya disease. Surg. Neurol. 2009;72:476–480. doi: 10.1016/j.surneu.2008.10.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.surneu.2008.10.009</ArticleId>
            <ArticleId IdType="pubmed">19147196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takagi Y., Kikuta K., Nozaki K., Fujimoto M., Hayashi J., Imamura H., Hashimoto N. Expression of hypoxia-inducing factor-1 alpha and endoglin in intimal hyperplasia of the middle cerebral artery of patients with Moyamoya disease. Neurosurgery. 2007;60:338–345. doi: 10.1227/01.NEU.0000249275.87310.FF.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1227/01.NEU.0000249275.87310.FF</ArticleId>
            <ArticleId IdType="pubmed">17290185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin R., Xie Z., Zhang J., Xu H., Su H., Tan X., Tian D., Su M. Clinical and immunopathological features of Moyamoya disease. PLoS ONE. 2012;7:e36386.  doi: 10.1371/journal.pone.0036386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0036386</ArticleId>
            <ArticleId IdType="pmc">PMC3338675</ArticleId>
            <ArticleId IdType="pubmed">22558457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujimura M., Fujimura T., Kakizaki A., Sato-Maeda M., Niizuma K., Tomata Y., Aiba S., Tominaga T. Increased serum production of soluble CD163 and CXCL5 in patients with moyamoya disease: Involvement of intrinsic immune reaction in its pathogenesis. Brain Res. 2018;1679:39–44. doi: 10.1016/j.brainres.2017.11.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2017.11.013</ArticleId>
            <ArticleId IdType="pubmed">29174692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung J.W., Kim D.H., Oh M.J., Cho Y.H., Kim E.H., Moon G.J., Ki C.S., Cha J., Kim K.H., Jeon P., et al.  Cav-1 (Caveolin-1) and arterial remodeling in adult Moyamoya disease. Stroke. 2018;49:2597–2604. doi: 10.1161/STROKEAHA.118.021888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/STROKEAHA.118.021888</ArticleId>
            <ArticleId IdType="pubmed">30355208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noda A., Suzuki Y., Takayasu M., Watanabe K., Takagi T., Hara M., Yoshida J. Elevation of nitric oxide metabolites in the cerebrospinal fluid of patients with moyamoya disease. Acta Neurochir. 2000;142:1275–1279. doi: 10.1007/s007010070025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s007010070025</ArticleId>
            <ArticleId IdType="pubmed">11201643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling—In control of vascular function. Nat. Rev. Mol. Cell Biol. 2006;7:359–371. doi: 10.1038/nrm1911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm1911</ArticleId>
            <ArticleId IdType="pubmed">16633338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaipersad A.S., Lip G.Y., Silverman S., Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J. Am. Coll. Cardiol. 2014;63:1–11. doi: 10.1016/j.jacc.2013.09.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2013.09.019</ArticleId>
            <ArticleId IdType="pubmed">24140662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto M., Aoyagi M., Fukai N., Matsushima Y., Yamamoto K. Differences in cellular responses to mitogens in arterial smooth muscle cells derived from patients with moyamoya disease. Stroke. 1998;29:1188–1193. doi: 10.1161/01.STR.29.6.1188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.STR.29.6.1188</ArticleId>
            <ArticleId IdType="pubmed">9626293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morishita R., Sakaki M., Yamamoto K., Iguchi S., Aoki M., Yamasaki K., Matsumoto K., Nakamura T., Lawn R., Ogihara T., et al.  Impairment of collateral formation in lipoprotein(a) transgenic mice: Therapeutic angiogenesis induced by human hepatocyte growth factor gene. Circulation. 2002;105:1491–1496. doi: 10.1161/01.CIR.0000012146.07240.FD.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.CIR.0000012146.07240.FD</ArticleId>
            <ArticleId IdType="pubmed">11914260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houkin K., Ito M., Sugiyama T., Shichinohe H., Nakayama N., Kazumata K., Kuroda S. Review of past research and current concepts on the etiology of moyamoya disease. Neurol. Med. Chir. 2012;52:267–277. doi: 10.2176/nmc.52.267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2176/nmc.52.267</ArticleId>
            <ArticleId IdType="pubmed">22688062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paschalaki K.E., Randi A.M. Recent advances in endothelial colony forming cells toward their use in clinical translation. Front. Med. 2018;5:295. doi: 10.3389/fmed.2018.00295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmed.2018.00295</ArticleId>
            <ArticleId IdType="pmc">PMC6205967</ArticleId>
            <ArticleId IdType="pubmed">30406106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tokunaga K., Date I. Moyamoya disease. Brain Nerve. 2008;60:37–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18232331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boylan J.F., Gudas L.J. The level of CRABP-I expression influences the amounts and types of all-trans-retinoic acid metabolites in F9 teratocarcinoma stem cells. J. Biol. Chem. 1992;267:21486–21491. doi: 10.1016/S0021-9258(19)36635-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0021-9258(19)36635-9</ArticleId>
            <ArticleId IdType="pubmed">1328234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mikami T., Suzuki H., Komatsu K., Mikuni N. Influence of Inflammatory disease on the pathophysiology of Moyamoya disease and quasi-Moyamoya disease. Neurol. Med. Chir. 2019;59:361–370. doi: 10.2176/nmc.ra.2019-0059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2176/nmc.ra.2019-0059</ArticleId>
            <ArticleId IdType="pmc">PMC6796064</ArticleId>
            <ArticleId IdType="pubmed">31281171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonveaux P., Martinive P., DeWever J., Batova Z., Daneau G., Pelat M., Ghisdal P., Gregoire V., Dessy C., Balligand J.L., et al.  Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ. Res. 2004;95:154–161. doi: 10.1161/01.RES.0000136344.27825.72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.RES.0000136344.27825.72</ArticleId>
            <ArticleId IdType="pubmed">15205364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park Y.S., Min K.T., Kim T.G., Lee Y.H., Cheong H.J., Yeom I.S., Choi J.U., Kim D.S., Kim N.K. Age-specific eNOS polymorphisms in moyamoya disease. Childs Nerv. Syst. 2011;27:1919–1926. doi: 10.1007/s00381-011-1504-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00381-011-1504-z</ArticleId>
            <ArticleId IdType="pubmed">21691823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai D., Lu Q., Huang Q., Yang P., Hong B., Xu Y., Zhao W., Liu J., Li Q. Serum miRNA signature in Moyamoya disease. PLoS ONE. 2014;9:e102382.  doi: 10.1371/journal.pone.0102382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0102382</ArticleId>
            <ArticleId IdType="pmc">PMC4122349</ArticleId>
            <ArticleId IdType="pubmed">25093848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uchino H., Ito M., Kazumata K., Hama Y., Hamauchi S., Terasaka S., Sasaki H., Houkin K. Circulating miRNome profiling in Moyamoya disease-discordant monozygotic twins and endothelial microRNA expression analysis using iPS cell line. BMC Med. Genom. 2018;11:72.  doi: 10.1186/s12920-018-0385-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12920-018-0385-3</ArticleId>
            <ArticleId IdType="pmc">PMC6114494</ArticleId>
            <ArticleId IdType="pubmed">30157848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee M.J., Fallen S., Zhou Y., Baxter D., Scherler K., Kuo M.F., Wang K. The impact of Moyamoya disease and RNF213 mutations on the spectrum of plasma protein and MicroRNA. J. Clin. Med. 2019;8:1648.  doi: 10.3390/jcm8101648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm8101648</ArticleId>
            <ArticleId IdType="pmc">PMC6832561</ArticleId>
            <ArticleId IdType="pubmed">31658621</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
